Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.

ABSTRACT:

Importance

Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting.

Objective

To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2.S and the mRNA vaccine BNT162b2.

Design, setting, and participants

In this cohort study at a single clinical site in Boston, Massachusetts, 68 individuals who were vaccinated at least 6 months previously with 2 immunizations of BNT162b2 were boosted with either Ad26.COV2.S or BNT162b2. Enrollment of participants occurred from August 12, 2021, to October 25, 2021, and this study involved 4 months of follow-up. Data analysis was performed from November 2021 to February 2022.

Exp

SUBMITTER: Tan CS 

PROVIDER: S-EPMC9366542 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature